Skip to main content
SpringerLink
Log in

Ruxolitinib and peripheral neuropathy: causal link?

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. UMC = Uppsala Monitoring Centre

References

  1. Bradley T. Ruxolitinib and peripheral neuropathy. WHO Pharmaceuticals Newsletter : 19-22, No. 4, Aug 2017. Available from: URL: http://apps.who.int/iris/bitstream/10665/258800/1/WPN-2017-04-eng.pdf?ua=1.

  2. Novartis. Response from Novartis (re Ruxolitinib and peripheral neuropathy). WHO Pharmaceuticals Newsletter : 22-24, No. 4, Aug 2017. Available from: URL: http://apps.who.int/iris/bitstream/10665/258800/1/WPN-2017-04-eng.pdf?ua=1.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ruxolitinib and peripheral neuropathy: causal link?. Reactions Weekly 1668, 5 (2017). https://doi.org/10.1007/s40278-017-35477-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-017-35477-8

Search

Navigation